Physician profile
Karan Chawla
NPI 1780181610
$4,409.96
in general payments reported to CMS, 2019-2025
23 companies · $2,318 in 2025
The $2,318 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $211 · 2022: $27.43 · 2023: $269 · 2024: $1,584 · 2025: $2,318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,989 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,988.56 |
| Education | $183.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $518.06 | 2024-2025 | Tremfya, Stelara |
| Inari Medical, INC. | $495.93 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Qol Medical, LLC | $393.04 | 2024-2025 | Sucraid, Sucraid |
| Boston Scientific Corporation | $340.50 | 2023-2025 | Obsidio, General - Hemostasis, General - Endochoice |
| Madrigal Pharmaceuticals | $334.95 | 2024-2025 | Rezdiffra, Resmetirom |
| Conmed Corporation | $324.77 | 2024-2025 | Conmed Generators, Conmed Biliary, Conmed Hemostasis |
| Phathom Pharmaceuticals, INC. | $246.33 | 2024-2025 | Voquezna |
| Abbvie INC. | $227.34 | 2024-2025 | |
| Shockwave Medical, INC | $219.03 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $210.97 | 2021 | |
| Braintree Laboratories, INC. | $146.06 | 2024-2025 | Sutab, Suflave |
| Lemaitre Vascular, INC. | $145.22 | 2025 | Artegraft Vascular Graft |
| Gilead Sciences, INC. | $124.82 | 2024 | Livdelzi |
| Ardelyx, INC. | $115.18 | 2024-2025 | Ibsrela |
| Baxter Healthcare | $100.00 | 2025 | Perclot |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $87.90 | 2024-2025 | |
| Lilly USA, LLC | $71.92 | 2024-2025 | Omvoh |
| Aimmune Therapeutics, INC. | $71.65 | 2024-2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $70.21 | 2025 | Dupixent |
| Ethicon US, LLC | $60.35 | 2025 | Harmonic, Enseal X1, Echelon Flex |
| Takeda Pharmaceuticals U.S.A., INC. | $57.66 | 2024-2025 | Eohilia, Entyvio |
| Medtronic, INC. | $27.43 | 2022 | |
| Intra-Sana Laboratories | $20.64 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karan Chawla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.